Data gathered: December 4
Data Bits
Data Bits | Value / Change | Benchmark | |
---|---|---|---|
Job Posts | 0% |
|
|
Sentiment | 100 0% |
|
|
Webpage traffic | 7,000 41.4% |
|
|
Linkedin Employees | 12 N/A |
|
|
4chan Mentions | 0% |
|
|
Facebook Engagement | 2 100% |
|
|
Facebook followers | 214 0.5% |
|
|
Stocktwits Mentions | 16 0% |
|
|
Stocktwits Subscribers | 1,364 0% |
|
|
Twitter Followers | 204 0% |
|
|
Instagram Followers | 88 0% |
|
|
News Mentions | 0% |
|
|
Reddit Mentions | 0% |
|
In the news
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QNovember 29 - Yahoo |
|
Ocean Biomedical receives Nasdaq notice regarding late filing of quarterly report on Form 10-QNovember 28 - Seeking Alpha |
|
Ocean Biomedical receives Nasdaq notice over late filingNovember 28 - Thefly.com |
|
![]() |
Virgin Galactic Flies Science Experiments to the Edge of SpaceNovember 15 - Universe Today |
![]() |
Ferro Silicon Market worth $12.9 billion by 2028 - Exclusive Report by MarketsandMarkets™November 13 - PR Newswire UK |
Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion TherapeuticsNovember 13 - Yahoo |
About Ocean Biomedical
Ocean Biomedical is a new-generation American biopharmaceutical company based in Providence, Rhode Island. The company has product candidates addressing malaria, pulmonary fibrosis, and lung cancer.

Price | $0.83 |
Target Price | Sign up |
Market Cap | $28M |
Dividend Yield | 0 |
Industry | Biotechnology |
Similar companies
Financial performance View All
Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | |
---|---|---|---|---|---|
Q2 '23 | 0 | 2.7M | -4.2M | -13M | -2.7M |
Q1 '23 | 0 | 12M | -27M | -67M | -18M |
Q4 '22 | 0 | 0 | 0 | 410,000 | 0 |
Q3 '22 | 0 | 0 | 0 | -1M | -1M |
Q2 '22 | 0 | 3.7M | -3.8M | -7.3M | -6.9M |
Insider Transactions
AJJARAPU SURENDRA K filed to buy 5,411,000 shares at $1. March 2 '23 |